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Integration of genetic and metabolic proﬁling holds promise for providing insight into human
disease. Coronary artery disease (CAD) is strongly heritable, but the heritability of metabolomic
proﬁles has not been evaluated in humans. We performed quantitative mass spectrometry-based
metabolic proﬁling in 117 individuals within eight multiplex families from the GENECARD study of
premature CAD. Heritabilities were calculated using variance components. We found high
heritabilities for amino acids (arginine, ornithine, alanine, proline, leucine/isoleucine, valine,
glutamate/glutamine, phenylalanine and glycine; h
2¼0.33–0.80, P¼0.005–1.9 10
 16), free fatty
acids (arachidonic, palmitic, linoleic; h
2¼0.48–0.59, P¼0.002–0.00005) and acylcarnitines
(h
2¼0.23–0.79, P¼0.05–0.0000002). Principal components analysis was used to identify metabolite
clusters. Reﬂecting individual metabolites, several components were heritable, including
components comprised of ketones, b-hydroxybutyrate and C2-acylcarnitine (h
2¼0.61); short- and
medium-chain acylcarnitines (h
2¼0.39); amino acids (h
2¼0.44); long-chain acylcarnitines
(h
2¼0.39) and branched-chain amino acids (h
2¼0.27). We report a novel ﬁnding of high
heritabilities of metabolites in premature CAD, establishing a possible genetic basis for these
proﬁles. These results have implications for understanding CAD pathophysiology and genetics.
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Introduction
Coronary artery disease (CAD) is the leading cause of death in
industrialized countries and, in concert with the epidemic of
obesity and diabetes, is rapidly becoming the leading cause of
death in developing countries (World Health Organization,
2002). The genetic predilection of CAD is well established;
familyhistoryhasbeenshowntobeanindependentriskfactor
for CAD (Shea et al, 1984), especially in early-onset forms
(Rissanen, 1979). Despite this, the genetic architecture of CAD
remains largely unknown.
Given the complex nature of CAD, evaluation of the disease
withmorecomprehensiveanalyticaltoolsmayprovideneeded
insights into biological pathways converging on this pheno-
type. High-throughput molecular proﬁling methods have
become increasingly prevalent in basic and clinical research.
Further, many commonly accepted risk factors for CAD are
metabolic. Metabolomics, the study of small-molecule meta-
bolites,maybeusefulforunderstandingmetabolicimbalances
and for diagnosis of human disease. Studies using unbiased
metabolomic proﬁling have uncovered differences in proﬁles
in myocardial ischemia (Sabatine et al, 2005), and have been
suggested to predict the presence and severity of CAD (Brindle
et al, 2002). However, another group has refuted the initial
CAD ﬁndings (Kirschenlohr et al, 2006). In both studies, the
majority of the analytes within the proﬁle remained unidenti-
ﬁed, making clinical and mechanistic interpretation difﬁcult,
and precluding correlation of the proﬁles with underlying
genetics. More recently, targeted metabolite proﬁling studies
have demonstrated heritability of metabolites in plants
(Keurentjes et al, 2006) and mice (Ferrara et al, 2008), but
this has never been explored in humans.
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www.molecularsystemsbiology.comTherefore, in this study, we have performed quantitative
proﬁlingof66metabolites,includingacylcarnitinespecies(by-
products of mitochondrial fatty acid, carbohydrate and amino-
acid oxidation), amino acids and free fatty acids, in plasma
samples from eight large multiplex families heavily burdened
with premature CAD. Our main goal was to perform a pilot
study to test whether metabolites are heritable in families
burdened with CAD, and to investigate the role of metabo-
lomic proﬁles in etiologic heterogeneity in CAD pathogenesis.
Results
Heritability analysis
Metabolic proﬁling was performed on 117 individuals within
eight multiplex Caucasian families (Supplementary informa-
tion) from the GENECARD study of premature CAD. Of note,
themajorityoffamilymemberssampledforthisstudywereas-
yet-unaffected offspring of the original affected sibling pair,
but who, as members of these families, were at high risk for
development of premature CAD. As expected,therewasa high
burden of CAD risk factors, although the prevalence differed
between families (Supplementary information).
Consistent with prior reports (Beekman et al, 2002), we
found high heritabilities for conventional risk factors such
as lipids and body mass index (BMI) (Figure 1). Total ketones
(h
2¼0.75, P¼3.8 10
 8) had the highest heritability among
the metabolites analyzed by non-mass spectrometry-based
methods, with similarly high heritability of the individual
ketone b-hydroxybutyrate (HBUT; h
2¼0.51, P¼0.004). Among
analytes measured by mass spectrometry, several amino acids
had high heritability (Figure 2; Supplementary information).
Arginine (ARG) had the highest score (h
2¼0.80,
P¼1.9 10
 16), with strong heritabilities also for glutamine/
glutamate (GLX; h
2¼0.73, P¼0.00006), alanine (ALA;
h
2¼0.55, P¼0.00002), proline (PRO; h
2¼0.52, P¼0.00004),
ornithine (ORN; h
2¼0.48, P¼0.000005), phenylalanine (PHE;
h
2¼0.46, P¼0.0001) and the branched-chain amino acids
leucine/isoleucine (LEU/ILE; h
2¼0.39, P¼0.00005) and valine
(VAL; h
2¼0.44, P¼0.00006). Of the free fatty acids (Figure 2),
FA-C20:4 (arachidonic acid, a key component in inﬂammatory
pathways) was the most heritable (h
2¼0.59, P¼0.00005), as
well as FA-C18:2 (linoleic acid, precursor to arachidonic acid,
h
2¼0.48, P¼0.002). Many acylcarnitines also had high
heritabilities (Figure 3; Supplementary information), the
highest being the C18 acylcarnitines (C18, C18:1, and C18:2;
h
2¼0.39–0.82, P¼0.0000007–0.004); C14:1 (h
2¼0.79,
P¼0.0000002); C5:1 (h
2¼0.67, P¼0.000003); the C10s (C10-
OH:C8-DC, C10 and C10:1; h
2¼0.35–0.57, P¼0.00003–0.02);
C16(h
2¼0.57, P¼0.0002);C4:Ci4(h
2¼0.56, P¼0.00003);short
chain dicarboxylacylcarnitines (C5-DC, C6-DC; h
2¼0.45–0.51,
P¼0.003–0.004) and C2 acylcarnitine (h
2¼0.50, P¼0.00008).
Interestingly, estimates for the genetic component of the
variability of each metabolite often exceeded the proportion of
variance explained by clinical covariates (Supplementary
information).
Metabolomic proﬁles within families
Given these strong ﬁndings, we sought to understand
quantitative differences in metabolites between families.
Multivariate linear models were used to test for the differences
in metabolites between families. Of the amino acids, gluta-
mate, ornithine, arginine, proline, histidine, phenylalanine,
alanine and methionine (all Po0.0001), leucine/isoleucine
(Po0.0001) and valine (P¼0.003) best differentiated families.
Of the acylcarnitines, the C18 (C18, C18:1 and C18:2) and the
C14 acylcarnitines(C14 and C14:1) (all Po0.0001), along with
C5:1 (Po0.0001) and C2 (Po0.0001) acylcarnitines best
differentiated families. Many free fatty acids differentiated
families, the strongest being arachidonic and palmitic acid
(both Po0.0001). Of the conventional metabolites, ketones
(Po0.0001) and b-hydroxybutyrate (P¼0.0001) best differen-
tiated families.
Principal components analysis (PCA)
Given the correlation of metabolites in biological pathways,
we performed PCA to understand which clusters of metabo-
lites were correlated and to identify factors that were most
heritable. Fifteen factors were identiﬁed, demonstrating
biologicallyconsistent relationships (Table I). Factorsaccount-
ing for the largest amount of variance within the data set were
factor 1 (short- and medium-chain acylcarnitines); factor 2
(long-chain free fatty acids); factor 3 (long-chain acylcarni-
tines and amino acids (arginine, glutamate/glutamine and
ornithine) possibly reporting on mitochondrial function);
factor 4 (ketones, b-hydroxybutyrate, C2 and C4-OH (b-
hydroxybutryl) acylcarnitines; all markers of terminal steps
of fatty acid oxidation) and factor 5 (amino acids, including
branched-chain amino acids and C3 and C5 acylcarnitines (by-
products of branched-chain amino-acid catabolism)). As
expected, given the results for individual metabolites, many
factors were heritable.
Discussion
In this study, we have applied a comprehensive set of
analytical tools to gain a better understanding of the bio-
chemical and physiologic underpinnings of cardiovascular
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Figure 1 Heritabilities of conventional metabolites. Heritabilities of the
conventional metabolites are displayed in graphical form. The Y-axis is the
negative log10 of the P-value for the heritability estimate (X-axis). Error bars
around heritability point estimates are in light gray.
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known genetic component of CAD risk. We performed
targeted, quantitative metabolic proﬁling in multiplex families
burdened with premature CAD, the majority representing
offspring of the affected generation that had not yet
developed CAD, but in whom we hypothesized similar
metabolic proﬁles as their affected family members, if such
proﬁles were heritable. In fact, we found high heritabilities for
many metabolites, many with higher heritabilities than for
conventional risk factors. These high heritabilities suggest a
strong correlation between genotype and phenotype, implying
a strong genetic component to clustering of these metabolic
signatures in families burdened with CAD. This study
represents the ﬁrst evaluation of the heritability of metabolite
proﬁles in humans, extending upon prior studies in plants
(Keurentjes et al, 2006) and mice (Ferrara et al, 2008).
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Figure 2 Heritabilities of amino acids and free fatty acids. Heritabilities of amino acids and free fatty acids are displayed in graphical form. The Y-axis is the negative
log10 of the P-value for the heritability estimate (X-axis). Error bars around heritability point estimates are in light gray.
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Figure 3 Heritabilities of acylcarnitines. Heritabilities of the acylcarnitines are displayed in graphical form. The Y-axis is the negative log10 of the P-value for the
heritability estimate (X-axis). Error bars around heritability point estimates are in light gray.
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individual metabolites distinguished families, the most pro-
minent being, among the amino acids, arginine, ornithine and
glutamate/glutamine; and among the lipid-derived metabo-
lites, the long-chain acylcarnitines C18:0, C18:1 and C18:2.
These ﬁndings suggest fundamental differences in mitochon-
drial function in these families, consistent with prior studies
showing relationships between impaired mitochondrial func-
tion and insulin resistance (Petersen et al, 2003;An et al, 2004;
Koves et al, 2005, 2008; Muoio and Newgard, 2008). Further
studies are necessary to clarify the underlying mechanisms
reﬂective of these differences.
We recognize that our study has some limitations. Given
our sample size, some results had large standard errors
despite strong statistical signiﬁcance. However, it should
be noted that the sample size of this study exceeds the limited
number of previous human studies and was adequate to
detect signiﬁcant heritabilities. Given our studies were
hypothesis generating, we did not adjust for multiple
comparisons. However, with a Bonferroni correction at the
level of the factors, nine factors remain signiﬁcant (Po0.003).
We did not account for dietary pattern (known inﬂuence
on metabolites), renal function, or medications (unknown
inﬂuence). To help minimize these ‘non-genetic’ effects, we
incorporated a household effect and included married-in
individuals, partially controlling for shared nutritional and
other environmental effects. The measures of household
effects suggest minimal inﬂuence on heritability estimates
with high heritabilities despite adjustment. Therefore,
we believe our results reﬂect both underlying genetic
and environmental effects, similar to traditional cholesterol
parameters. Accordingly, we found a signiﬁcant household
effect for low-density lipoprotein (LDL)-cholesterol (propor-
tion of variance due to household 0.11, P¼0.02), but with a
signiﬁcant heritability despite adjustment for this environ-
mental effect (h
2¼0.37, P¼0.004).
Similarly, resultscould reﬂect differences in essential versus
non-essential metabolites. However, we found similar herit-
abilities for the essential (h
2¼0.40, P¼0.0004) and non-
essential (h
2¼0.63, P¼0.00002) amino acids when analyzed
as groups, and for the essential (h
2¼0.50, P¼0.003) compared
withthenon-essential(h
2¼0.33,P¼0.03)fattyacids.Although
underpowered for such analyses, we also examined the
relationship of age with heritabilities related to these groups.
Age was a signiﬁcant covariate on heritability estimates for
both essential (valine) and non-essential (proline, ornithine
and citrulline) amino acids (Supplementary information). For
the free fatty acids, age was a covariate only for non-essential
fatty acids (palmitoleic, oleic and stearic acid). We also
examined correlations of metabolites with age and found that
both essential (tyrosine and linoleic acid) and non-essential
(glutamine, ornithine, citrulline and oleic acid) metabolites
were signiﬁcantly correlated with age (data not shown).
Therefore, there does not seem to be a consistent variation of
metabolites with age, nor with heritability estimates, based on
essential/non-essential groups. This may indicate that funda-
mental and genetically controlled metabolic processes (e.g.
mitochondrial or microsomal catabolic pathways) are inﬂuen-
cing the levels of both essential and non-essential metabolites
that utilize these common elements of the metabolic machin-
ery. Larger, population-based studies should delve deeper into
these questions.
Table I Principal components analysis in GENECARD
Factors Metabolites within factor
a Overall description of factor Eigenvalue Total
var
Cum
var
Heritability
(SD)
P-value
1 C2, C6-DC, C8, C8:1, C10, C10:1,
C10:3, C10-OH:C8-DC, C12, C12:1,
C14, C14:1, C14:2, C14:1-OH, C14-
OH:C12-DC
Short- and medium-chain
acylcarnitines
11.88 0.20 0.20 0.39 (0.16) 0.0006
2 Total FFA, FA-C14:0, FA-C16:0, FA-
C16:1, FA-C18:0, FA-C18:1, FA-C18:2,
FA-C18:3
Free fatty acids 7.55 0.13 0.32 0.35 (0.20) 0.02
3 ARG, GLX, ORN, C16, C18, C18:1,
C18:2
Amino acids, long-chain
acylcarnitines (markers of
overall mitochondrial
function)
5.89 0.10 0.42 0.40 (0.18) 0.002
4 C2, C4-OH, C14:1, C14:2, C14:1-OH,
Ket, Hbut
FFA oxidation by-products 3.51 0.06 0.48 0.61 (0.17) 0.00004
5 ALA, LEU/ILE, MET, PRO, TYR, VAL,
PHE, C5, C3, C20
Metabolites involved in
amino-acid catabolism
2.98 0.05 0.53 0.27 (0.15) 0.01
6 CIT, C5-DC, C8:1, C10:3 Various 2.36 0.04 0.57 0.51 (0.17) 0.0008
7 SER, GLY, CIT, MET Amino acids 2.04 0.03 0.60 0.44 (0.28) 0.09
8 C14-OH:C12-DC, C18:1-OH, C22 Various 1.89 0.03 0.64 0.40 (0.18) 0.003
9 C12-OH:C10-DC, C14, C14:1-OH, C20 Various 1.86 0.03 0.67 0.51 (0.17) 0.0003
10 C3, C4:Ci4, C22 Various 1.67 0.03 0.69 0.46 (0.19) 0.002
11 ASX, HIS Amino acids 1.48 0.02 0.72 0.33 (0.17) 0.005
12 FAC22:6, FAC20:4, C20 Long-chain free fatty acids 1.37 0.02 0.74 0.36 (0.17) 0.007
13 C16-OH:C14-DC Various 1.24 0.02 0.76 0.46 (0.20) 0.002
14 PRO, ALA, C18:1-DC Various 1.18 0.02 0.78 0.54 (0.16) 0.0001
15 C18-DC:C20-OH Various 1.06 0.02 0.80 0.45 (0.19) 0.006
FFA, free fatty acids; tot var, total variance; cum var, cumulative variance.
Results ofPCAinthedatasetarepresented,including thekeymetabolites withineach factor (i.e.thosewithafactor loadX|0.4|); anoverallbiochemical description of
the key metabolites within each factor; and the eigenvalue, total and cumulative variance, heritability and P-value for the heritability point estimate for each factor.
aFactor load X|0.4|.
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include variability in sample collection or processing. We
used a standardized protocol to limit this type of variability,
intra-individual variation was low in a set of repeated assays,
and family members were collected at different locations and
times. Finally, it is important to note that our heritability
estimates, bydesign, are for families burdenedwith premature
CAD, and therefore are not generalizable to a population
without a genetic burden for CAD.
A major strength of the study is the use of a very accurate,
targeted, quantitative approach to metabolomic proﬁling,
allowing us to dissect biological mechanisms underlying
CAD pathophysiology. Previous studies involving application
of metabolomics to cardiovascular disease involved primarily
non-targeted proﬁling and small sample sizes, and used
modeling that is difﬁcult to understand clinically and hard to
integrate into our knowledge of pathophysiology. Another
strength of our study is that we performed metabolite proﬁling
within a family-based design. Using this approach, one can
potentially distinguish shared environmental versus genetic
inﬂuences, and develop hypotheses regarding metabolic and
genetic risk in a sample of high-risk, as-of-yet unaffected
offspring.
Our results have implications for future studies of CAD.
Explicitly accounting for the heterogeneity introduced by the
distinct metabolomic signatures, as we have done previously
with conventional metabolites (Shah et al, 2006), may be
important for mapping of CAD genes and for understanding
theunderlying genetic architectureof these metabolite proﬁles
(so called ‘mQTLs’) (Ferrara et al, 2008). In addition to
furthering the understanding of CAD pathophysiology, these
results may have signiﬁcant implications for risk prediction.
Future studies should include reﬁning results in other cohorts,
mapping the genes underlying these heritabilities and under-
standing the predictive capabilities of metabolites in non-
familial cohorts.
Materials and methods
Study population
TheGENECARDstudyenrolled920familiestoperformaffectedsibling
pair linkage for the identiﬁcation of genes for early-onset CAD (before
the age of 51 years for men and 56 years for women) (Hauser et al,
2003).Familieswithatleasttwosiblingseachofwhommetthecriteria
forearly-onsetCAD(beforetheageof51yearsformenand56yearsfor
women) were recruited. Unaffected family members were deﬁned as
no clinical evidence of CAD and age greater than 55 years for men
(greater than 60 years for women). From this cohort, we selected eight
representative families we believed would be particularly informative,
based on the availability of a relatively large number of family
members and a heavy burden of CAD in the proband and surrounding
generations (Supplementary information). These families were
recontacted; the affected sibling pair and family members not
previously enrolled were ascertained regardless of CAD, focused on
offspring of the affected sibling pair. This ascertainment strategy was
based on the hypothesis that if abnormalities in metabolic proﬁles
preceded development of CAD in these families, that signiﬁcant
concordance of metabolite levels within families would be evident
even in the absence of overt CAD in the offspring. Sample collections
within a given family were carried out at several different times and at
different locations, by a single experienced phlebotomist. Blood
samples were promptly processed after collection through peripheral
venous phlebotomy (within minutes), frozen as soon as possible
thereafter (at most within 12h with the majority of samples being
frozen within 1–2h of collection), and stored as plasma samples in
EDTA-treated tubes at  801C. Samples were collected as often as
possibleinafastingstate;however,theconsistencyofthiscouldnotbe
determined. Institutional Review Boards approved study protocols;
informed consent was obtained from each subject.
Biochemical measurements
Frozen plasma samples were used to quantitatively measure targeted
metabolites, including 37 acylcarnitine species, 15 amino acids, 9 free
fatty acids and conventional analytes, ketones and C-reactive
protein (CRP). Sample preparation and coefﬁcients of variation have
been reported (Haqq et al, 2005). The laboratory was blinded to
family identiﬁers and case–control status. Assay ranges are 0.05–
40mM (acylcarnitines); 5–1000mM (amino acids) and 1–1000mmol/l
(fatty acids). For simplicity, the clinical shorthand of metabolites is
used (Supplementary information). Intra-individual variability was
assessed in samples from ﬁve individuals for which repeat proﬁling
was performed on the same sample on ﬁve separate days. Coefﬁcients
of variation and correlation conﬁrmed minimal inter-assay variability
(Supplementary information).
Conventional metabolite analysis
Standard clinical chemistry methods were used for conventional
metabolites, including glucose, total cholesterol, high-density lipopro-
tein (HDL)- and LDL-cholesterol, and triglycerides with reagents from
Roche Diagnostics (Indianapolis, IN); and free fatty acids (total) and
ketones (total and 3-hydroxybutyrate) with reagents from Wako
(Richmond, VA). All measurements were performed using a Hitachi
911 clinical chemistry analyzer.
Acylcarnitines and amino acids
Proteins were ﬁrst removed by precipitation with methanol. Aliquoted
supernatants were dried, and then esteriﬁed with hot acidic methanol
(acylcarnitines) or n-butanol (amino acids). Acylcarnitines and amino
acids were analyzed by tandem MS with a Quattro Micro instrument
(Waters Corporation, Milford, MA). In total, 37 acylcarnitine species
and 15 amino acids in plasma were assayed by our previously
described methods (Millington et al, 1990; An et al, 2004; Wu et al,
2004). Leucine/isoleucine (LEU/ILE) are reported as a single analyte
because they are not resolved by our MS/MS method, and include
contributions from allo-isoleucine and hydroxyproline. Under normal
circumstances,theseisobaricaminoacidscontributelittletothe signal
attributed to LEU/ILE (Chace et al, 1995). In addition, the acidic
conditions used to form butyl esters results in partial hydrolysis of
glutaminetoglutamicacidandofasparaginetoaspartate.Accordingly,
values that are reported as GLU/GLN or ASP/ASN are not meant to
signify the molar sum of glutamate and glutamine, or of aspartate and
asparagine, but rather measure the amount of glutamate or aspartate
plus the contribution of the partial hydrolysis reactions of glutamine
and asparagine, respectively.
Free fatty acids
Free fatty acids were gently methylated using iodomethane and
puriﬁed by solid-phase extraction (Patterson et al, 1999). Derivatized
fatty acids were analyzed by capillary gas chromatography/mass
spectrometry (GC/MS) using a Trace DSQ instrument (Thermo
Electron Corporation, Austin, TX). Owing to sample volume con-
siderations, free fattyacid measurementswere performedonly in 80 of
the 117 individuals (ﬁve out of eight families).
All mass spectrometric analyses used stable isotope dilution.
Quantiﬁcation of the foregoing ‘targeted’ intermediary metabolites
was facilitated by the addition of mixtures of known quantities of
stable isotope internal standards to samples from Isotec (St Louis,
MO), Cambridge Isotope Laboratories (Andover, MA) and CDN
Isotopes (Pointe-Claire, Quebec, CN) (Supplementary information).
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Heritabilities were calculated using the Sequential Oligogenic
Linkage Analysis Routines (SOLAR) software version 4.0.7 (Almasy
and Blangero, 1998), which uses maximum-likelihood methods to
estimate variance components, allowing incorporation of ﬁxed effects
for known covariates and variance components for genetic effects.
This approach appropriately accounts for correlation between all
family members and allows incorporation of extended pedigrees such
as that are present in the current study. The total variation is
partitioned into components for additive genetic variance and
environmental variance, as well as a residual (unexplained) varia-
bility. The program uses the pedigree covariance matrix
O ¼ 2F
s2
g þ Is2
e
where O is the covariance matrix, F is the matrix of kinship values, s2
g
is the additive genetic variance, I represents the identity matrix,
and se
2 is the random environmental variance (Almasy and Blangero,
1998). This model allows for complex pedigree data (i.e. beyond
parent–offspring pairs) and hence, the resulting heritability estimates
are more accurate than those obtained using only nuclear family
members. For the current study, all sampled individuals from the
pedigree were entered into the variance component models, including
unaffected offspring, cousins and married-in family members.
Incorporation of married-infamily members (i.e. genetically unrelated
but with shared environment) allows for better estimation of the
environmental component of intrafamilial clustering of traits.
Valuesconsideredoutlierswereexcludedfromheritabilityanalyses,
deﬁned as values falling outside of the mean±4 s.d. (1–2 outliers for
each of 24 of the metabolites). Metabolite measurements below the
lowerlimitsofquantiﬁcation(LOQ)weregiven avalueofLOQ/2.Four
metabolites having 425% of samples below LOQ were not further
analyzed (C6, C5-OH:C3-DC, C4DC and C10:2 acylcarnitines). All
measurements were natural log-transformed prior to analysis, result-
ing in most metabolites approximating a normal distribution, an
important consideration for variance components analysis. Eighteen
metabolitesdid not meet this criterion,and therefore, linearregression
models adjusted for body mass index (BMI), age, sex, CAD, diabetes
mellitus (DM (yes/no), hypertension (yes/no) and dyslipidemia (yes/
no) were constructed for each of these metabolites, and the residuals
were used for heritability estimates. Given the occasional low trait
standard deviations for metabolites (o0.5), all log-transformed
metabolites were multiplied by a factor of 4.7 prior to analysis.
Polygenic heritability models were then constructed. For the
normally distributed metabolites (the majority of metabolites),
polygenic heritability models were calculated using the log-trans-
formed values, adjusting for age, sex, BMI, DM, dyslipidemia,
hypertension and CAD. The proband and family members were not
selected based on any metabolite values; however, the potential for
ascertainmentbiasexists.Therefore,analyseswerecorrectedbasedon
which of the family members (proband) was the index member for
ascertainment ofthe familyforearly-onset CAD.To account for factors
such as diet (which are shared in households but are presumably not
genetic), an additional variance component parameter corresponding
to the fraction of variance associated with the effect of a common
household (included in the model by a marker for residential address)
was added to each model. All residual kurtoses for the ﬁnal polygenic
model were within normal range (i.e. o0.8), except for two amino
acids (serine and phenylalanine), 11 acylcarnitines (C5, C10, C10:1,
C10:3, C12:1, C14, C14-OH:C12-DC, C16-OH:C14-DC, C18:1-OH,
C18:1-DC and C18-DC:C20-OH) and 3 free fatty acids (FAC14:0,
FAC16:1 and FAC18:1). For these metabolites, removal of 1–4 of the
most extreme values was necessary, which then resulted in a normal
residual kurtosis. Two acylcarnitines required removal of a larger
numberofoutlierstoachievea normalresidualkurtosis(C16-OH:C14-
DC and C12-OH:C10-DC), and hence, these results should be
interpreted accordingly. For the 18 non-normally distributed metabo-
lites, standardized residuals from adjusted regression models were
used to estimate heritabilities using SOLAR, but as the normalized
deviates were already adjusted for relevant covariates heritability
models using these residuals were not further adjusted. Estimates of
theproportionofvarianceexplainedbyclinicalcovariatesarereported
for these non-normally distributed metabolites as estimated using the
adjusted polygenic model constructed from the log-transformed
crude values.
For understanding quantitative differences in metabolites between
families, multivariate generalized linear models adjusted for sex, age,
BMI, CAD, DM, dyslipidemia and hypertension were used to compare
mean metabolite levels between families.
Unsupervised PCA
Given that many metabolites reside in overlapping pathways,
correlation of metabolites is expected. To understand the correlation,
we used PCA to reduce the large number of correlated variables
(Supplementary information) into clusters of fewer uncorrelated
factors using raw metabolite values without removal of outliers. The
factor with the highest ‘eigenvalue’ accounts for the largest amount of
the variability within the data set. Standardized residuals calculated
for each metabolite from linear regression models adjusted for age,
sex, BMI, DM and CAD were used as inputs for PCA. PCA using
residuals is recommended when, as in this case, the units for each
variablevarysigniﬁcantlyinmagnitude(JohnsonandWichern,1988).
Factors with an eigenvalue X1.0 were identiﬁed based on the
commonly used Kaiser criterion (Kaiser, 1960). Varimax rotation was
then performed to produce interpretable factors. Metabolites with a
factor load X|0.4| are reported as composing a given factor, as is
commonly used as an arbitrary threshold (Lawlor et al, 2004). Scoring
coefﬁcients were then used to compute factor scores for each
individual (consisting of a weighted sum of the values of the
standardized metabolites within that factor, weighted on the factor
loading calculated for each individual metabolite). These factor scores
were thenusedtocalculateheritabilitiesforeachfactorwithSOLARas
detailed above, using a polygenic model not further adjusted for
covariates. Removal of 1–4 of the most extreme values for several of
the factors was necessary to achieve a normal residual kurtosis.
As all analyses were exploratory in nature and given collinearity of
the metabolites, nominal two-sided P-values unadjusted for multiple
comparisons are presented; however, results interpreted in the context
of a conservative Bonferroni correction are reported in the Discussion.
Nominal statistical signiﬁcance was deﬁned as P-valuep0.05.
Statistical analyses used SAS version 9.1 (SAS Institute, Cary, NC),
other than for heritability estimates that used SOLAR (Almasy and
Blangero, 1998).
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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